Clinical Trials Browser

Phase 1/2 × OTHER × ALX148 × Clear all

NCT05025800 2025-10-09

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma